TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01151839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Patient with squamous cell carcinoma of esophagus will be treated with surgery alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemoradiation followed by surgery
Description: Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
Study: NCT03910660

Intervention type: DRUG
Group type: OTHER
Intervention: BXCL701 plus Pembrolizumab
Description: BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle.
Study: NCT04738903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted LASIK eye surgery
Description: FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted LASIK eye surgery
Description: FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
Study: NCT02749318

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IL-1 genetic test for risk of severe periodontitis
Description: DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
Study: NCT03057639

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03134651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT03910660

Intervention type: DRUG
Group type: OTHER
Intervention: BXCL701 plus Pembrolizumab
Description: BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: BXCL701 plus Pembrolizumab
Description: BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: BXCL701 monotherapy
Description: BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.
Study: NCT02050763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The SHARE Project
Description: SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior.
Study: NCT02076451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8273a
Description: DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8273a
Description: DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8273a
Description: DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
Study: NCT03117062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occlusal reduction
Description: relief of occlusion following endodontic treatment
Study: NCT00677690

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation (NMES)
Description: NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham electrical stimulation
Description: Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
Study: NCT02562417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT04054843

Intervention type: DIAGNOSTIC_TEST
Intervention: Afamin
Description: Plasma maternal afamin levels
Study: NCT02076451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8273a
Description: DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
Study: NCT04484415

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cevira®
Description: The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo device is identical in appearance as the Cevira® device, but does not provide light.
Study: NCT01568918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Description: Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
Study: NCT02641990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 20/60 mcg/day, ITCA placebo
Description: ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA placebo, ITCA 650 20/60 mcg/day
Description: ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
Study: NCT04233931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP medication adherence mobile app
Description: Participants use a PrEP medication adherence mobile app for six weeks.
Study: NCT04337307

Intervention type: BIOLOGICAL
Intervention: Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators
Description: Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony.

Intervention type: BIOLOGICAL
Intervention: Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators
Description: Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony.
Study: NCT02562417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Study: NCT02521818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIA Diet for Seniors
Study: NCT02631876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be administered per dose and schedule specified in the arm.
Study: NCT03204916

Intervention type: BEHAVIORAL
Intervention: Discussion
Description: Participate in focus group

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Data abstraction and central review

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT01464554

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: alcohol and drug education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Free Talk
Description: motivational interviewing alcohol and drug program
Study: NCT00937651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan (BR-A-657•K) 20 mg
Description: Fimasartan 20 mg, 1 tablet + placebo, 2 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan (BR-A-657•K) 60 mg
Description: Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan (BR-A-657•K) 180 mg
Description: Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
Study: NCT02560779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab (TRC105)
Description: Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg of sorafenib will be given twice daily.
Study: NCT01937247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be inducted in the induction room
Description: The patients will be inducted in the induction room

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Redesigned process
Description: The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patient will be reversed with sugammadex 4mg/kg IV
Description: The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: STANDARD PROCESS
Description: standard process
Study: NCT00868296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Study: NCT05466344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst Group
Description: 1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFBC Group
Description: 1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient.
Study: NCT02234752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine XR
Study: NCT03557359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
Study: NCT03022669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
Study: NCT03810976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin, gemcitabine
Description: Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
Study: NCT01658059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy
Description: drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy
Description: drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
Study: NCT00668200

Intervention type: DRUG
Group type: OTHER
Intervention: Reclast (ZOL446, zoledronic acid)
Description: 5 mg i.v. annually (real-life, physician prescribed)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium
Description: 1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
Study: NCT01658059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
Study: NCT04750083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
Study: NCT02001246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real Deal program for Anger Management
Description: Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body Bridging (MBB) program
Description: MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
Study: NCT06324032

Intervention type: PROCEDURE
Intervention: EUS Elastography (EUS-E)
Description: All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
Study: NCT00285779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept 50 mg twice weekly for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01065220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testolactone undecanoate
Description: 4ml i.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lynestrenol
Description: 2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate
Description: 50mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 100 microgram TTS twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitor
Description: 1mg daily
Study: NCT01283750

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: care coordination
Description: dementia-related care coordination
Study: NCT01317719

Intervention type: PROCEDURE
Intervention: Distal Biceps Re-Insertion Surgery
Description: Surgical Repair of the Distal Biceps Tendon
Study: NCT03520413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRACTICE-DM
Description: Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
Study: NCT01678521

Intervention type: PROCEDURE
Intervention: LDL-apheresis
Description: The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
Study: NCT00730886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Description: Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myomectomy
Description: Invasive surgical procedure for fibroid removal